Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.55 |
| ▸ | PPARG | P37231 | 4/20 | 0.55 |
| ▸ | FBP1 | P09467 | 9/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655256 | 0.86 | PPARA (0.56) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL1549310 | 0.85 | PPARA (0.58) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL2668303 | 0.82 | PPARA (0.50) | PPARAPPARGCYP1A2CYP3A4TSHR | |
| SCHEMBL2655891 | 0.80 | PPARA (0.53) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL11208625 | 0.80 | PPARA (0.53) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL31222160 | 0.80 | PPARA (0.53) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL197882 | 0.79 | PPARA (0.64) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL20730087 | 0.79 | PPARA (0.64) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL12670824 | 0.78 | PPARA (0.62) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL4422408 | 0.77 | PPARA (0.68) | PPARAPPARGFBP1ABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940900-B2 | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application | ADVINUS THERAPEUTICS PRIVATE LIMITED (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2125735-B1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2012-06-27 | — | — | EP | disclosed |
| US-20100144772-A1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-06-10 | — | — | US | disclosed |
| EP-2125735-A2 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | Advinus Therapeutics Private Limited (IN) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008104994-A2 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144772-A1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | GCK, GCKR, GALK1 | PPARA 658/4885PPARG 486/4885FBP1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.